Loading Regimen，Serum Trough Concentrations，Efficacy and Safety in Pneumonia Patients With Gram-positive Infections

Pneumonia Gram-Positive Bacterial Clinical Trial

Official title:

A Retrospective Study of Relationships Between Loading Regimen，Serum Trough Concentrations，Efficacy and Safety in Pneumonia Patients With Gram-positive Infections Treated With Teicoplanin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03229135
• Other study ID #: LZhou
• Status: Completed
• Phase: N/A
• First received: July 19, 2017
• Last updated: July 21, 2017
• Start date: February 1, 2015
• Est. completion date: October 30, 2016

Study information

• Verified date: July 2017
• Source: People's Hospital of Zhengzhou University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This was a retrospective study that all teicoplanin-treated adult patients with Gram-positive infections admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from February 2015 to August 2016.

Description:

1. Patients and protocol This was a retrospective study that all teicoplanin-treated adult patients with Gram-positive infections admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from February 2015 to August 2016. Patients were included who met the following criteria: (1) age≥18 years, (2) duration of teicoplanin therapy≥5 days, (3) written informed consent was obtained from each patients. Patients were excluded who fulfilled any of the following criteria: (1) Patients who were allergy to teicoplanin, (2) pregnant women, (3) patients with hematopoietic function, (4) patients unable to evaluate efficacy and safety. This study was approved by the research ethics committee of the Zhengzhou Central Hospital affiliated to Zhengzhou University.

2. Treatment regimen and groups According to CLcr and teicoplanin loading dose regimen, all patients were divided into four groups. Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d. Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d. Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d. Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d. The maintenance dosing was adjusted by Cmin and CLcr in all groups. The target Cmin was set to 15~30 mg/L. If Cmin<15 mg/L or >30 mg/L, the maintenance dosage was increased or decreased appropriately up to target Cmin range. CLcr values for male and female were calculated based on the following equations, respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. completion date: October 30, 2016
• Est. primary completion date: August 20, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age=18 years

• duration of teicoplanin therapy=5 days

• written informed consent was obtained from each patients

Exclusion Criteria:

• Patients who were allergy to teicoplanin

• pregnant women

• patients with hematopoietic function

• patients unable to evaluate efficacy and safety

Related Conditions & MeSH terms

• Pneumonia
• Pneumonia Gram-Positive Bacterial
• Pneumonia, Bacterial

Intervention

Device:
• other antibacterial agents,breathing machine
If treatment failure for patients in group A,group B,group C and group D,change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
People's Hospital of Zhengzhou University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum teicoplanin trough concentrations	Teicoplanin trough samples were taken immediately 30 minutes before teicoplanin administration on the fourth day. Blood samples for 2-3 mL were collected in blood-collection tubes without any additives and centrifuged at 3500 rpm for 10min. Serum teicoplanin trough concentrations (Cmin) were determined by a high-performance liquid chromatography method as previously described. The detections were completed in Translational Medicine Center of Zhengzhou Central Hospital affiliated to Zhengzhou University.	0.5 hour before teicoplanin administration on the fourth day
Secondary	White blood cell count (WBC)	It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years
Secondary	C-reaction protein (CRP)	It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years
Secondary	Asparttate aminotransferase (AST)	It is an indicator of liver function.It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years
Secondary	Alanine aminotransferase (ALT)	It is an indicator of liver function.It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years
Secondary	Serum creatinine (Scr)	It is an indicator of renal function.It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years
Secondary	CLcr	It is an indicator of renal function.It was completed before initiation and after completion of teicoplanin therapy in Zhengzhou city clinical inspection center.	2 years